Medical therapy of IBD in 2009.
Harris
Adam
A
Rhode Island Hospital, Gastroenterology Department, Providence, RI 02903, USA. aharris2@lifespan.org
Feller
Edward R
ER
Shah
Samir A
SA
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000178:diet therapy / Q000188:drug therapy* / Q000601:surgery; D015122:Mercaptopurine / Q000627:therapeutic use; D019804:Mesalamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D000069442:Natalizumab; D019936:Probiotics / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine; D019804:Mesalamine; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate